TSX runs higher on rate cut expectations
Fate Therapeutics Inc (NASDAQ:FATE) President and CEO Bahram Valamehr sold 14,466 shares of common stock on August 4, 2025, according to a new SEC filing. The transaction comes as the stock has experienced a 9.4% decline over the past week, with shares currently trading at $1.08. According to InvestingPro analysis, the company, currently valued at $123.8 million, holds more cash than debt on its balance sheet. The shares were sold at a weighted average price of $1.0643, for a total transaction value of $15,396. Prices ranged from $1.04 to $1.07.
The sale was to cover tax withholding obligations related to the vesting of 25,000 shares of common stock underlying restricted stock units granted on July 29, 2024. These sales were automatically executed pursuant to an irrevocable election by Valamehr to satisfy tax obligations through "sell-to-cover" transactions.
Following the transaction, Valamehr directly owns 334,898 shares of Fate Therapeutics. For deeper insights into FATE’s valuation and 13 additional ProTips, visit InvestingPro, where you’ll find comprehensive analysis and the detailed Pro Research Report available for this stock.
In other recent news, Fate Therapeutics presented promising clinical data for its FT819 therapy at the European Alliance of Associations for Rheumatology Congress in Barcelona. The therapy, aimed at treating lupus, showed significant results, with all three patients suffering from severe lupus nephritis achieving Primary Efficacy Renal Response. Notably, one patient remains in drug-free remission after a year. H.C. Wainwright and Needham both maintained their Neutral and Hold ratings, respectively, on Fate Therapeutics following these developments. Meanwhile, BofA Securities adjusted its price target for the company to $2.20, down from $2.50, while also maintaining a Neutral rating. The data presented included longer follow-up periods for patients who received a fludarabine-free conditioning regimen. Additionally, an extrarenal lupus patient achieved a Low Lupus Disease Activity State, maintained over six months. These developments highlight ongoing research efforts and potential advancements in lupus treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.